In Latest News, Publication and DataPosted November 3, 2023 Tallac Presents First Clinical Data for TAC-001 at SITC 2023
In Latest NewsPosted September 27, 2023 Tallac Therapeutics Announces Two Abstracts Accepted for Presentation at Society for Immunotherapy of Cancer (SITC) 2023 Annual Meeting
In Latest NewsPosted January 19, 2023 Tallac Therapeutics Appoints Kevin N. Heller, M.D., as Chief Medical Officer
In Latest NewsPosted November 11, 2022 Tallac Therapeutics Presents Data for Two, First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugates at the Society for Immunotherapy of Cancer 37th Annual Meeting
In Latest NewsPosted July 28, 2022 Tallac Therapeutics Announces First Patient Dosed with TAC-001, a First-in-Class Toll-like Receptor 9 Agonist Antibody Conjugate, in a Phase 1/2 Study for Patients with Advanced Solid Tumors
In Latest NewsPosted May 19, 2022 Tallac Therapeutics Announces FDA Clearance of Investigational New Drug (IND) Application for TAC-001, a First-in-Class Toll-like Receptor 9 (TLR9) Agonist Antibody Conjugate for Patients with Advanced Solid Tumors
In Latest NewsPosted April 15, 2021 Tallac Therapeutics Appoints Curtis Hecht as Chief Business Officer
In Latest NewsPosted March 4, 2021 ALX Oncology and Tallac Therapeutics Announce Collaboration on Novel Class of Cancer Immunotherapeutics
In Latest NewsPosted December 1, 2020 Tallac Therapeutics Launches with $62 Million in Series A Financing to Advance Novel Immunotherapies for Cancer
